Jonathan Faison runs the
ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics (0:30). Data risk for Ogsiveo and Mirdametinib (5:50).
This is an excerpt from a recent episode.Show Notes:
Biotech's Hidden Gems: Smart Strategies For A Challenging MarketSpringWorks Therapeutics Q3 2024 Earnings Call TranscriptRead the transcriptsFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at
seekingalpha.com/subscriptions